On 27 to 31 July, PROMINENT partners presented new work at the Alzheimer’s Association International Conference (AAIC) 2025 in Toronto, Canada. In related conference news, Eisai and Biogen presented an interim two-year real-world analysis of lecanemab in 178 people with early Alzheimer’s disease treated at US centres, reporting clinical stability in most patients, with amyloid-related imaging abnormalities and discontinuation rates consistent with label guidance and growing use of blood-based biomarkers.
PROMINENT, funded by the Innovative Health Initiative, is developing a digital platform to integrate diagnostic data and provide personalised decision support for clinicians managing cognitive impairment, starting with Alzheimer’s disease. On 27 July, Lena Sannemann (University of Cologne, Germany) presented the poster “Evaluation and validation of a precision medicine platform in neurodegenerative disease (PROMINENT)”.
“I had the opportunity to present the study design of the PROMINENT evaluation and validation studies as a poster presentation on the first day of the conference. The poster attracted considerable interest and allowed me to share the aims of the PROMINENT clinical studies and discuss the relevance of digital decision support solutions to assist clinicians in the diagnosis and treatment of neurodegenerative disorders. It was a great opportunity to introduce PROMINENT to a wider audience, and it was lovely to meet my colleagues working on the project!” said Lena Sannemann.
Further PROMINENT contributions included an oral presentation by Alina Solomon (University of Eastern Finland) on using digital biomarkers to monitor disease progression, and a poster by Sophie van der Landen (Alzheimer Center Amsterdam, Netherlands) on test–retest reliability and feasibility of the web-based cognitive assessment cCOG.
“I was pleased to present our findings on the test–retest reliability and feasibility of cCOG, a web-based cognitive assessment tool. During the conference, it became clear that digital cognitive testing is increasingly discussed alongside emerging biomarkers, such as blood-based biomarkers. This highlights the growing recognition that combining different types of digital and biological measures will be essential to improve early detection and monitoring of cognitive impairment. PROMINENT provides an ideal framework to integrate these complementary data sources and translate them into practical decision support for clinicians,” reflected Sophie van der Landen.